Enterprise Value

135.2M

Cash

177.6M

Avg Qtr Burn

-68.18M

Short % of Float

8.08%

Insider Ownership

0.87%

Institutional Own.

61.93%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Roxadustat (ROW) Details
Chronic kidney disease, Anemia

Approved

Quarterly sales

Roxadustat Details
Chemotherapy Induced Anemia

PDUFA

Approval decision

Pamrevlumab Details
Cancer, Pancreatic cancer

Big Mover™

Susp. Mover™

Phase 3

Data readout

Pamrevlumab Details
Duchenne muscular dystrophy

Phase 3

Update

Roxadustat Details
Myelodysplastic syndrome, Anemia

Phase 3

Update

Pamrevlumab Details
Pancreatic cancer, Cancer

Big Mover™

Susp. Mover™

Phase 2/3

Data readout

FG-3246+ enzalutamide Details
Cancer, Castration-resistant prostate cancer

Phase 2

Initiation

FG-3246 (ADC) Details
Cancer, Castration-resistant prostate cancer

Phase 2

Initiation

FG-3165 Details
Cancer, Solid tumor/s

Phase 1

Initiation

Pamrevlumab Details
COVID-19, Infectious disease

Failed

Discontinued

Roxadustat (U.S.) Details
Anemia, Chronic kidney disease

Failed

Discontinued

Pamrevlumab Details
Idiopathic pulmonary fibrosis

Failed

Discontinued